News
Moderna’s mRNA flu shot outperforms existing vaccines in Phase 3 trial, showing over 26% greater efficacy—paving the way for ...
For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.
The U.S. Food and Drug Administration is now requiring two common COVID-19 vaccines to update their warning labels to include ...
The FDA has updated labels on the top two COVID-19 vaccines to warn of a rare heart side effect, mostly seen in young men.
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback